¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"clear cell carcinoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • sebaceous carcinoma
    ÇÇÁö»ù¾ÏÁ¾, ±â¸§»ù¾ÏÁ¾
  • urothelial carcinoma
    ¿ä·Î»óÇǼ¼Æ÷¾ÏÁ¾
  • undifferentiated carcinoma
    ¹ÌºÐÈ­¾ÏÁ¾
  • verrucous carcinoma
    »ç¸¶±Í¸ð¾ç¾ÏÁ¾
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ÀºÄ£È­¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • spindle cell
    ¹æÃß¼¼Æ÷
  • stellate cell
    º°¼¼Æ÷
  • stem cell
    Áٱ⼼Æ÷
  • supporting cell
    ¹öÆÀ¼¼Æ÷
  • sustentacular cell
    (¢¡supporting cell) ¹öÆÀ¼¼Æ÷
  • target cell
    Ç¥Àû¼¼Æ÷
  • transitional cell
    ÀÌÇ༼Æ÷
  • cell line
    ¼¼Æ÷ÁÖ
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
  • sickle cell trait
    ³´¼¼Æ÷¼ÒÁú, ³´ÀûÇ÷±¸Çü¼º¼ÒÁú
  • packed cell volume
    ÃæÀü¼¼Æ÷¿ëÀû, ³óÃ༼Æ÷¿ëÀû
  • red cell distribution width
    ÀûÇ÷±¸ºÐÆ÷Æø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • acidophilic cell
    È£»ê¼º¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ģũ·ÒÀº¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • basal cell adenoma
    ±âÀú¼¼Æ÷»ùÁ¾, ¹Ù´Ú¼¼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Heidenhain s cell
    ÇÏÀ̵§ÇÏÀμ¼Æ÷.
  • Henle s cell
    Çî·¯¼¼Æ÷.
  • Hfr cell
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷
  • Hulle cell
    ¿ÜÇǼ¼Æ÷
  • ICSH = interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±Ø(Êàòõá¬øàí©Ð½)È£¸£¸ó.
  • ICSH=£¾interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó.
  • K cell
    K¼¼Æ÷, »ìÇØ¼¼Æ÷
  • LE cell
    LE¼¼Æ÷.
  • LE cell phenomenon
    LE¼¼Æ÷Çö»ó.
  • Langerhans cell
    ¶û°Ô¸£Çѽº¼¼Æ÷.
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº ¼¼Æ÷ Á¶Á÷±¸Áõ
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº¼¼Æ÷Á¶Á÷±¸Áõ
  • Langerhans giant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • Langhans giant cell
    ¶û±×Çѽº°Å´ë¼¼Æ÷
  • Leydig cell
    ·¹À̵ðÈ÷ ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • oat cell carcinoma
    ±Í¸®¼¼Æ÷¾ÏÁ¾(¡­äßðþ)
  • pigmented basal cell carcinoma
    »ö¼ÒÄ§Âø ±âÀú¼¼Æ÷¾Ï
  • renal cell carcinoma
    ½Å¼¼Æ÷¾Ï
  • renal cell carcinoma
    ½Å¼¼Æ÷¾ÏÁ¾(¡­á¬øàäßðþ)
  • rodent carcinoma => basal cell epithelioma
  • sclerosing basal cell carcinoma
    °æÈ­ ±âÀú¼¼Æ÷¾Ï
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾(á³á¬øàäßðþ)
  • solid basal cell carcinoma
    °íÇü¼º ±âÀú¼¼Æ÷¾Ï
  • spindle cell carcinoma
    ¹æÃ߻󼼯÷ ¾ÏÁ¾
  • spindle cell carcinoma
    ¹æÃß¼¼Æ÷¾ÏÁ¾(Û·õßá¬øàäßðþ)
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾ (¡­á¬øàäßðþ)
  • squamous cell carcinoma antigen
    ÆíÆò¼¼Æ÷¾ÏÁ¾Ç׿ø(ø·øÁá¬øàäßðþù÷ê«)
  • superficial basal cell carcinoma
    ¾èÀº ±âÀú¼¼Æ÷¾Ï
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • undifferentiated basal cell carcinoma
    ¹ÌºÐÈ­ ±âÀú¼¼Æ÷¾Ï
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Basal epithelial cell
    ¹Ù´Ú»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±âÀúÃþ»óÇǼ¼Æ÷
  • Basal cell
    ¹Ù´Ú¼¼Æ÷
    [¿¾ ¿ë¾î] ±âÀú¼¼Æ÷
  • Fusiform myoepithelial cell
    ¹æÃß±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó±Ù»óÇǼ¼Æ÷
  • Fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó³»ÇǼ¼Æ÷
  • Sustentacular cell
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Parietal cell
    º®¼¼Æ÷
    [¿¾ ¿ë¾î] º®¼¼Æ÷
  • Stellate myoepithelial cell
    º°±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó±Ù»óÇǼ¼Æ÷
  • Stellate cell
    º°¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼Æ÷
  • Cell of parathyroid gland
    ºÎ°©»ó»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ºÎ°©»ó¼±¼¼Æ÷
  • Secretory synovial cell
    ºÐºñÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·ºÐºñ¼¼Æ÷
  • Mast cell
    ºñ¸¸¼¼Æ÷
    [¿¾ ¿ë¾î] ºñ¸¸¼¼Æ÷
  • Intercalated epithelial cell
    »çÀÌ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Áß°£Ãþ»óÇǼ¼Æ÷
  • Interstitial cell
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Epithelial reticular cell
    »óÇǼ¼¸Á¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǼº¼¼¸Á¼¼Æ÷
  • Pigment epithelial cell
    »ö¼Ò»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • K cell
    K ¼¼Æ÷(á¬øà)
  • killer cell
    »ì¼¼Æ÷(ß¯á¬øà)
  • memory cell
    ±â¾ï¼¼Æ÷(ÑÀåãá¬øà)
  • natural killer cell
    ÀÚ¿¬ »ì¼¼Æ÷(í»æÔß¯á¬øà)
  • NK cell
    NK ¼¼Æ÷(á¬øà)
  • nonpermissive cell
    ºñÇã¿ë ¼¼Æ÷(ÞªúÉé»á¬øà)
  • null cell
    ¹«Ç¥Áö¼¼Æ÷(Ùíøúò½á¬øà)
  • permanent cell strain
    ¿µ±¸¼¼Æ÷ÁÖ(çµÎùá¬øàñ»)
  • permissive cell
    Çã¿ë ¼¼Æ÷(úÉé»á¬øà)
  • photoelectric cell
    ±¤ÀüÁö(ÎÃï³ò®)
  • photovoltaic cell
    ±¤ÀüÁö (ÎÃï³ò®)
  • plaque forming cell
    ÇöóÅ© Çü¼º ¼¼Æ÷(û¡à÷á¬øà)
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà)
  • primed cell
    °¨ÀÛ¼¼Æ÷(ÊïíÂá¬øà)
  • productive cell
    »ý»ê ¼¼Æ÷(ßæß§á¬øà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • sickle-cell anemia
    °â»ó(Àû)Ç÷±¸¼ººóÇ÷
  • signet-ring cell
    ¹ÝÁö¼¼Æ÷, ÀÎȯ¼¼Æ÷
  • small cell
    ¼Ò¼¼Æ÷
  • small cleaved cell
    ¼ÒºÐÇÒ¼¼Æ÷
  • spindle cell
    ¹æÃ߻󼼯÷
  • stem cell
    °£¼¼Æ÷
  • stromal cell
    °£Áú¼¼Æ÷
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • tumor cell
    Á¾¾ç¼¼Æ÷
  • white blood cell
    ¹éÇ÷±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
TCC terminal complement complex; thromboplastic cell component; transitional-cell carcinoma; trichloroca...
GC ganglion cell; gas chromatography; general circulation; general closure; general condition; generali...
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
BCC Basal Cell Carcinoma
SCC   1) Sude Chain-Cleavage Complex
  2) Squamous Cell Carcinoma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
SCLC Small Cell Carcinoma
SCLC Small Cell Lung Carcinoma
SCC Small cell carcinoma
SCCL Small cell carcinoma of the lung
SCC Squamous Cell Carcinoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • medullary carcinoma
    ¼öÁú¼º ¾ÏÁ¾
  • mucinous breast carcinoma
    Á¡¾×¼º À¯¹æ ¾Ï
  • nonseminomatous testicular carcinoma
    ºñÁ¤»ó ÇÇÁ¾¼º °íȯ ¾Ï
  • palate carcinoma
    ±¸°³ ¾Ï
    ±¸°³ºÎ¿¡ ¹ß»ýÇÑ ¾Ï.
  • papillary carcinoma
    À¯µÎ¾Ï, À¯µÎ»ó ¾ÏÁ¾
    1. À¯µÎ ¸ð¾çÀÇ Áõ½ÄÀÌ ÀÖ´Â ¾ÏÁ¾. 2. À¯µÎ»ó ¼ºÀåÀ» ÇÏ´Â ¸ðµç °©»ó¼± Á¾¾çÀ» ÀÌ ¹üÁÖ¿¡ ³Ö´Â´Ù. ¼ø¼öÈ÷ À¯µÎ»ó ±¸Á¶¸¸ ÀÖ´Â °ÍÀÌ ¾Æ´Ï¶ó ¿©Æ÷»ó ±¸Á¶°¡ ¼¯¿© Àֱ⵵ ÇÏ´Ù. ´ëºÎºÐÀÇ À¯µÎ»ó ¾ÏÁ¾Àº ¹«Å뼺ÀÌ°í ¿¹Èİ¡ ¸Å¿ì ÁÁ´Ù. 10-20%¿¡¼­ ±¹¼Ò ¸²ÇÁÀýÀÇ ÀüÀÌ·Î °æºÎ ¸²ÇÁÀý Á¾´ë°¡ ù Áõ»óÀÌ´Ù. À¯µÎ»ó ¾ÏÁ¾Àº Àü °©»ó¼± ¾ÏÁ¾ÀÇ 75-85%·Î °©»ó¼± ¾ÏÁ¾ Áß °¡Àå ÈçÇϸç 20´ë ³»Áö 60´ë¿¡ È£¹ßÇϰí 40¼¼ ÀÌÇÏ¿¡¼­´Â 80%ÀÇ ¾ÏÁ¾ÀÌ À¯µÎ»óÀÌ´Ù. ¿©¼ºÀÌ 2-3¹è ¸¹´Ù.
  • primary carcinoma
    ¿ø¹ß ¾ÏÁ¾
  • prostatic carcinoma
    Àü¸³¼± ¾Ï
  • salivary duct carcinoma
    Ÿ¾×¼±°ü »óÇǾÏ
    ´Ü´ÜÇÏ°í ¹«Å뼺ÀÎ Á¾¹°·Î, ³ôÀº ¾Ç¼ºµµ¸¦ ³ªÅ¸³»´Â Ÿ¾×¼±°ü¿¡ »ý±â´Â ¾Ç¼º Á¾¾ç.
  • scirrhous breast carcinoma
    °æÁú¼º À¯¹æ ¾Ï
  • thyroid carcinoma
    °©»ó¼± ¾Ï
    50´ëÀÇ ¿©¼º¿¡°Ô ÈçÈ÷ ³ªÅ¸³ª´Â °©»ó¼±ÀÇ ¾ÏÁ¾.
  • ulcerative carcinoma
    ±Ë¾ç¼º ¾ÏÁ¾
  • urothelial carcinoma
    ¿ä·Î »óÇÇ ¼¼Æ÷ ¾ÏÁ¾
  • virilizing adrenal carcinoma
    ³²¼ºÈ­ ºÎ½Å ¾ÏÁ¾
  • Abbe-Zeiss counting cell
    ¾Ðº£-ÀÚÀ̽º Ç÷±¸ °è»ê
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
carcinoma, adenosquamous A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
(12 Dec 1998)
carcinoma, adrenal cortical A malignant neoplasm of adrenal cortical cells demonstrating partial or complete histological and functional differentiation. They are rare, comprising between only 0.05% and 0.2% of all cancers. Women develop functional adrenal cortical carcinomas more commonly than men, but men develop nonfunctioning ones more often than women. Hypercortisolism is the most common presentation for this cancer. Virilism and cushing's syndrome may also result.
(12 Dec 1998)
carcinoma, basosquamous A skin carcinoma that histologically exhibits both basal and squamous elements.
(12 Dec 1998)
carcinoma, bronchogenic A cancer of the lung, so-called because it arises from the epithelium of the bronchial tree. It is not a histologic designation despite the name.
(12 Dec 1998)
carcinoma, ehrlich tumour A transplantable, poorly differentiated malignant tumour which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
(12 Dec 1998)
carcinoma, embryonal A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumours.
(12 Dec 1998)
carcinoma, endometrioid Ovarian carcinoma which resembles typical carcinoma of the endometrium and may be seen with a synchronous endometrial carcinoma. When they appear together, both tend to be of low stage.
(12 Dec 1998)
carcinoma ex pleomorphic adenoma <tumour> Carcinoma arising in a benign mixed tumour of a salivary gland, characterised by rapid enlargement and pain.
(05 Mar 2000)
carcinoma, hepatocellular Primary carcinoma of the liver cells. It ranges from a well-differentiated tumour difficult to distinguish from normal hepatocytes to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic or may form giant cells. Several classification schemes have been suggested. Hepatocellular carcinoma is very rare in the united states and western europe, but it is one of the most common cancers in eastern asia and sub-saharan africa. The cases are preponderantly male and, racially, whites have the lowest rates.
(12 Dec 1998)
carcinoma, infiltrating duct An invasive (infiltrating) carcinoma of the breast. This carcinoma in which no special histological feature is recognised is designated nos or not otherwise specified and is by far the most common ductal tumour, accounting for almost 70% of breast cancers. It is characterised by stony hardness upon palpation. It commonly metastasizes to the axillary lymph nodes and its prognosis is the poorest of the various ductal types.
(12 Dec 1998)
carcinoma in situ Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts.
(16 Dec 1997)
carcinoma, intraductal, noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterised by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. Its true incidence is uncertain but all noninvasive breast carcinomas comprise almost 5% of all neoplastic lesions of the female breast, with this carcinoma accounting for about 50% of these, or 2.5%-2.8% of all tumours.
(12 Dec 1998)
carcinoma, lewis lung A carcinoma discovered by dr. Margaret r. Lewis of the wistar institute in 1951. This tumour originated spontaneously as a carcinoma of the lung of a c57bl mouse. The tumour does not appear to be grossly haemorrhagic and the majority of the tumour tissue is a semifirm homogeneous mass. It is also called 3ll and llc and is used as a transplantable malignancy.
(12 Dec 1998)
carcinoma, lobular A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumours in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces.
(12 Dec 1998)
carcinoma, medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • storage cell
    ÃàÀüÁö;±â¾ï ´ÜÀ§
  • voltaic cell
    ÀüÁö
  • wet cell
    ½ÀÀüÁö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á